Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment.

ABSTRACT:

Background

It is assumed that loss of heterozygosity and allelic copy loss in HLA gene is associated with poor response rates in immune checkpoint inhibitor treatment. H-owever, the accurate extents or consistency in cancer types have not been explored.

Objective

The goal of this study is to investigate quantitative relationship between HLA allelic copy loss and response rates to immune checkpoint inhibitors. Also, tumor microenvironment was computationally assessed in the tumors with HLA copy loss to provide potential mechanisms for the relationships.

Method

A total of 282 whole exome sequencing data from three cohorts of patients who received immune checkpoint blockade immunotherapy were analyzed, including Anti-PDL1 treated in metastatic urothelial cancer (N = 216)

SUBMITTER: Yang Y 

PROVIDER: S-EPMC8921140 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature